|Bid||14.74 x 1300|
|Ask||14.76 x 800|
|Day's Range||14.37 - 14.92|
|52 Week Range||8.76 - 19.99|
|Beta (3Y Monthly)||1.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.89|
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 9.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ...
Flexion Therapeutics, Inc. (FLXN) and Xenon Pharmaceuticals Inc. (XENE) today announced that the companies have entered into a definitive agreement that provides Flexion with the global rights to develop and commercialize XEN402, a NaV1.7 inhibitor, for the management of post-operative pain. The initial development of FX301 is intended to support administration as a peripheral nerve block for control of post-operative pain.
The Compensation Committee of the Board of Directors approved the grants with an effective date of September 3, 2019. The stock options and restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $12.78 per share and vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company.
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
Unlike commercial-stage companies that have product revenues, drug startups largely rely on private equity funding, stock sales and debt financing to fund their operations. And those operations can be pricey.
BURLINGTON, Mass., Aug. 28, 2019 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate.
Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 9.43% and 20.81%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $17.0 million in Q2 representing 60% growth over Q1Completed debt.
In 2007 Mike Clayman was appointed CEO of Flexion Therapeutics, Inc. (NASDAQ:FLXN). This report will, first, examine...
Flexion Therapeutics, Inc. (FLXN) today announced that it will report its second-quarter 2019 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2019. Flexion Therapeutics (FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. For the past three years, Flexion has been named one of the Best Places to Work by the Boston Business Journal, and Flexion was recognized as a Top Place to Work in Massachusetts by The Boston Globe in 2017 and 2018.
Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
An analysis of clinical trial data indicates ZILRETTA reduced pain with similar improvements observed after each of two injections in patients with knee OA classified as.
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
Flexion Therapeutics, Inc. (FLXN) today announced that it has been named one of Boston Business Journal’s “Best Places to Work” for the third consecutive year. Flexion was the only Boston-area biopharmaceutical company recognized in the medium business category (100 to 249 employees). “There is tremendous competition for talent in the biotech industry, and awards like this differentiate Flexion and give us an advantage when it comes to attracting and retaining top talent,” said Michael Clayman, M.D., President and Chief Executive Officer of Flexion.
BURLINGTON, Mass., June 18, 2019 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate.